Figure 3.

Analysis of grafts surviving to 557 days. (A) Kaplan-Meier curve analysis of recipients who received genetically engineered porcine kidneys with or without tesidolumab included in the immunosuppression regimen. (B) H&E and confocal microscope analysis of rejected xenografts. Confocal microscopy showing deposition of IgM and C4d in the control and tesidolumab-treated recipients. Tesidolumab-treated recipients had minimal histological injury, while control kidneys had parenchymal hemorrhage and thrombotic microangiopathy. Deposition of C5b-9 was reduced on xenografts in tesidolumab-treated recipients.